These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 18814815)

  • 1. The prognostic value of vascular endothelial growth factor (VEGF)-A and its receptor in clinically localized prostate cancer: a prospective evaluation in 100 patients undergoing radical prostatectomy.
    Mao K; Badoual C; Camparo P; Delongchamps NB; Vieillefond A; Dinh-Xuan AT; Peyromaure M
    Can J Urol; 2008 Oct; 15(5):4257-62. PubMed ID: 18814815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma levels and expression of vascular endothelial growth factor-A in human localized prostate cancer.
    Peyromaure M; Badoual C; Camparo P; Grabar S; Goulvestre C; Fulla Y; Vieillefond A; Mao K; Dinh-Xuan AT
    Oncol Rep; 2007 Jul; 18(1):145-9. PubMed ID: 17549360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association of vascular endothelial growth factor receptor-1 with the risk of cancer progression following radical prostatectomy.
    Mao K; Camparo P; Badoual C; Peyromaure M; Delongchamps NB; Vieillefond A; Dinh-Xuan AT
    Oncol Rep; 2008 Jan; 19(1):171-5. PubMed ID: 18097592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer.
    George DJ; Regan MM; Oh WK; Tay MH; Manola J; Decalo N; Duggan S; Dewolf WC; Kantoff PW; Bubley GJ
    Urology; 2004 Feb; 63(2):327-32. PubMed ID: 14972483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy.
    Peyromaure M; Camparo P; Badoual C; Descazeaud A; Dinh-Xuan AT
    BJU Int; 2007 May; 99(5):1150-3. PubMed ID: 17437444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
    Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy.
    Shariat SF; Anwuri VA; Lamb DJ; Shah NV; Wheeler TM; Slawin KM
    J Clin Oncol; 2004 May; 22(9):1655-63. PubMed ID: 15117988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer.
    Seto T; Higashiyama M; Funai H; Imamura F; Uematsu K; Seki N; Eguchi K; Yamanaka T; Ichinose Y
    Lung Cancer; 2006 Jul; 53(1):91-6. PubMed ID: 16697074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate.
    Li R; Younes M; Wheeler TM; Scardino P; Ohori M; Frolov A; Ayala G
    Prostate; 2004 Feb; 58(2):193-9. PubMed ID: 14716745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy.
    Moul JW; Maygarden SJ; Ware JL; Mohler JL; Maher PD; Schenkman NS; Ho CK
    J Urol; 1996 Mar; 155(3):982-5. PubMed ID: 8583622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VEGFR1 and NRP1 endothelial expressions predict distant relapse after radical prostatectomy in clinically localized prostate cancer.
    Talagas M; Uguen A; Garlantezec R; Fournier G; Doucet L; Gobin E; Marcorelles P; Volant A; DE Braekeleer M
    Anticancer Res; 2013 May; 33(5):2065-75. PubMed ID: 23645757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes.
    Mori R; Dorff TB; Xiong S; Tarabolous CJ; Ye W; Groshen S; Danenberg KD; Danenberg PV; Pinski JK
    Prostate; 2010 Nov; 70(15):1692-700. PubMed ID: 20564320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased expressions of vascular endothelial growth factor (VEGF), VEGF-C and VEGF receptor-3 in prostate cancer tissue are associated with tumor progression.
    Yang J; Wu HF; Qian LX; Zhang W; Hua LX; Yu ML; Wang Z; Xu ZQ; Sui YG; Wang XR
    Asian J Androl; 2006 Mar; 8(2):169-75. PubMed ID: 16491267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant decrease in angiopoietin-1 and angiopoietin-2 after radical prostatectomy in prostate cancer patients.
    Caine GJ; Ryan P; Lip GY; Blann AD
    Cancer Lett; 2007 Jun; 251(2):296-301. PubMed ID: 17240049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced expression of heat shock protein 27 following neoadjuvant hormonal therapy is associated with poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer.
    Miyake H; Muramaki M; Kurahashi T; Yamanaka K; Hara I; Fujisawa M
    Anticancer Res; 2006; 26(2B):1583-7. PubMed ID: 16619575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary levels of vascular endothelial growth factor in patients with prostate cancer as a predictor of disease progression.
    Miyake H; Muramaki M; Kurahashi T; Yamanaka K; Hara I
    Anticancer Res; 2005; 25(5):3645-9. PubMed ID: 16101195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy.
    Shariat SF; Menesses-Diaz A; Kim IY; Muramoto M; Wheeler TM; Slawin KM
    Urology; 2004 Jun; 63(6):1191-7. PubMed ID: 15183988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer.
    Fukuda H; Tsuchiya N; Narita S; Kumazawa T; Horikawa Y; Inoue T; Saito M; Yuasa T; Matsuura S; Satoh S; Ogawa O; Habuchi T
    Oncol Rep; 2007 Nov; 18(5):1155-63. PubMed ID: 17914566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer.
    Gravdal K; Halvorsen OJ; Haukaas SA; Akslen LA
    Cancer Res; 2009 Jun; 69(11):4708-15. PubMed ID: 19487287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer.
    Carrillo de Santa Pau E; Arias FC; Caso Peláez E; Muñoz Molina GM; Sánchez Hernández I; Muguruza Trueba I; Moreno Balsalobre R; Sacristán López S; Gómez Pinillos A; del Val Toledo Lobo M
    Cancer; 2009 Apr; 115(8):1701-12. PubMed ID: 19197998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.